Alzheimer's disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Globally, the incidence of type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) epidemics is increasing rapidly and has huge financial and emotional costs. The purpose of the current review article is to discuss the shared pathophysiological connections between AD and T2DM. Research findings are presented to underline the vital role that insulin plays in the brain’s neurotransmitters, homeostasis of energy, as well as memory capacity. The findings of this review indicate the existence of a mechanistic interplay between AD pathogenesis with T2DM and, especially, disrupted insulin signaling. AD and T2DM are interlinked with insulin resistance, neuroinflammation, oxidative stress, advanced glycosylation end products (AGEs), mitochondrial dysfunction and metabolic syndrome. Beta-amyloid, tau protein and amylin can accumulate in T2DM and AD brains. Given that the T2DM patients are not routinely evaluated in terms of their cognitive status, they are rarely treated for cognitive impairment. Similarly, AD patients are not routinely evaluated for high levels of insulin or for T2DM. Studies suggesting AD as a metabolic disease caused by insulin resistance in the brain also offer strong support for the hypothesis that AD is a type 3 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269 · cited 2×
“It leads to oxidation of proteins, lipids and DNA, causing damage to the mitochondria, as well as induction of genetic mutations in DNA/RNA [91]).”
BackgroundSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“It is estimated that the global diabetes mellitus (DM) prevalence will rise from 9.3% (463 million people) in 2019 to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [8].”
BackgroundInfluentialHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“The strongest genetic risk factor for AD is the e4 allele of apolipoprotein E (APOE4) relative to the e3 allele and the protective e2 allele [5,6].”
BackgroundType 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662 · cited 2×
“This dysfunction means that the secretion of insulin by the β-cells of the pancreatic islets (β-cell dysfunction) as well as the action of insulin on insulin-sensitive tissues such as the liver, adipose tissue and muscle do not function normally for the body (insulin resistance) [9].”
BackgroundProtein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 1×
“AD and T2DM are both diseases that involve the formation of amyloid in various parts of the body [42,43].”
BackgroundAdvanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 1×
“These products are protein molecules or peptides that are formed as a result of the Maillard reaction, meaning they become glycated as a result of their exposure to sugars [105].”
BackgroundTau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 1×
“In its normal state, tau protein is responsible for microtubule stability and regulating intracellular signaling [63–66].”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175 · cited 1×
“Insulin resistance affects the way insulin works in target tissues and cells, leading to the well-known phenomenon of hyperglycemia, a condition in which too much glucose circulates in the blood plasma and characterizes T2DM [9] T2DM has also been associated with an increased risk of dementia [10,11] and of AD by 45–9…”
Background
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Metabolic Syndrome as a Risk Factor for Alzheimer’s Disease: A Focus on Insulin Resistance
Ezkurdia, A., Ramírez, M. J., & Solas, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054354 · Cited by 169
GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
Kalinderi, K., Papaliagkas, V. T., & Fidani, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073812 · Cited by 130
“Recent data highlight similarities between neurodegenerative diseases, including PD and type 2 diabetes mellitus (T2DM) [5], suggesting that the homeostasis in the gut–brain axis is fundamental for the maintenance of health in both central nervous system (CNS) and peripheral system, and these…”
BackgroundSelf-citationKim, O. Y., & Song, J. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122356 · Cited by 102
Giacomo, S. D., Percaccio, E., Gullì, M., Romano, A., Vitalone, A., Mazzanti, G., Gaetani, S., & Sotto, A. D. (2022) · Nutrients · doi:10.3390/nu14183709 · Cited by 95
“Moreover, other contributing factors, including the presence of neurofibrillary tangles containing hyperphosphorylated tau protein within neurons, neuroinflammation, neurotransmitter deficits, and neurodegeneration, which finally lead to neuronal death, have been highlighted [5].”
BackgroundFoxO1 as a tissue-specific therapeutic target for type 2 diabetes
Teaney, N. A., & Cyr, N. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1286838 · Cited by 89
True or false? Alzheimer’s disease is type 3 diabetes: Evidences from bench to bedside
Peng, Y., Yao, S.-Y., Chen, Q., Jin, H., Du, M., Xue, Y.-H., & Liu, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102383 · Cited by 96
Tian, Y., Jing, G., & Zhang, M. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101999 · Cited by 259
Al‐kuraishy, H. M., Jabir, M. S., Albuhadily, A. K., Al-Gareeb, A. I., & Rafeeq, M. F. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102084 · Cited by 80
Antidiabetic Drugs in the Treatment of Alzheimer’s Disease
Michailidis, M., Tata, D. A., Moraitou, D., Kavvadas, D., Karachrysafi, S., Papamitsou, T., Vareltzis, P., & Papaliagkas, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094641 · Cited by 69
“Recent research shows that AD shares many common links with diseases related to insulin resistance, such as neuroinflammation, insulin signaling disorder, oxidative stress, advanced glycosylation end products (AGEs), mitochondrial dysfunction, and metabolic syndrome [17].”
BackgroundSelf-citationWang, Y., Hu, H., Liu, X., & Guo, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1138499 · Cited by 76
“, 1986; Selkoe and Schenk, 2003) which is accompanied by synaptic dysfunction, neurogenesis, and neuronal disorders (Michailidis et al., 2022).”
BackgroundDing, X., Li, Y., Zhang, L., Zhang, Y., Zha, T., Zhang, W., Gui, B., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13882 · Cited by 73
Kim, Y., Lim, J., & Oh, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117277 · Cited by 71
Metabolic defects shared by Alzheimer's disease and diabetes: A focus on mitochondria
Carvalho, C., & Moreira, P. I. (2023) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2023.102694 · Cited by 67
It’s not the thought that counts: Allostasis at the core of brain function
Theriault, J. E., Katsumi, Y., Reimann, H. M., Zhang, J., Deming, P., Dickerson, B. C., Quigley, K. S., & Barrett, L. F. (2025) · Neuron · doi:10.1016/j.neuron.2025.09.028 · Cited by 73
Associations between Diabetes Mellitus and Selected Cancers
Pliszka, M., & Szablewski, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137476 · Cited by 61
“Note that Alzheimer’s disease is also named type 3 diabetes mellitus (T3DM) [7].”
BackgroundPelle, M. C., Zaffina, I., Giofrè, F., Pujia, R., & Arturi, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411301 · Cited by 52
“Moreover, A accumulation stimulates serine phosphorylation of insulin receptor substrate-1 (IRS-1), consequently impairing insulin signaling, releasing inflammatory molecules, and contributing to brain insulin resistance [82].”
BackgroundPan, Y., Li, J., Lin, P., Wan, L., Qu, Y., Cao, L., & Wang, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1348410 · Cited by 54
Sim, A. Y., Choi, D. H., Kim, J. Y., Kim, E. R., Goh, A. R., Lee, Y., & Lee, J. E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115755 · Cited by 50
Melatonin—A Powerful Antioxidant in Neurodegenerative Diseases
Kołodziejska, R., Woźniak, A., Bilski, R., Wesołowski, R., Kupczyk, D., Porzych, M., Wróblewska, W., & Pawluk, H. (2025) · Antioxidants · doi:10.3390/antiox14070819 · Cited by 55
“This results in improved glucose transport, increased ATP availability, and reduced oxidative stress in conditions of insulin resistance [112–115].”
Khoramipour, K., Bejeshk, M. A., Rajizadeh, M. A., Najafipour, H., Dehghan, P., & Farahmand, F. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03285-z · Cited by 48
“However, because IR is commonly seen in early AD (hence called type 3 diabetes [12]), adiponectin might be a vital player in AD [13].”
BackgroundType 2 Diabetes and Alzheimer’s Disease: The Emerging Role of Cellular Lipotoxicity
Marrano, N., Biondi, G., Borrelli, A., Rella, M., Zambetta, T., Gioia, L. D., Caporusso, M., Logroscino, G., Perrini, S., Giorgino, F., et al. (2023) · Biomolecules · doi:10.3390/biom13010183 · Cited by 51
“It is well known that impaired glucose metabolism, insulin resistance, inflammation, oxidative stress, amyloid accumulation, advanced glycosylation end products accrual, and mitochondrial dysfunction are biological events that occur in both T2D and AD (reviewed in [9,19]), such that AD has been recently designated as…”
BackgroundUrkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 45
“Early epidemiological observations identified a higher incidence of AD among T2DM patients [30,31], leading to the recognition of the shared pathophysiological characteristics of the diseases [32].”
Kazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
“Impor-tantly, type 2 diabetes mellitus shares common pathophysiological mechanisms with AD, leading to the view of AD as “type 3 diabetes” [108].”
BackgroundRabieipoor, S., Zare, M., Ettcheto, M., Camins, A., & Javan, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17873 · Cited by 42
Wang, M., Xie, K., Zhao, S., Jia, N., Zong, Y., Gu, W., & Cai, Y. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00727-1 · Cited by 44
“In addition, insulin may also affect cognitive function through neural inflammation, oxidative stress, and neuronal apoptosis (Michailidis et al. 2022).”
BackgroundSkawratananond, S., Xiong, D. X., Zhang, C., Tonk, S. S., Pinili, A., Delacruz, B., Pham, P., Smith, S. C., Navab, R., & Reddy, P. H. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102732 · Cited by 42
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42
Zhong, S., Xiao, C., Li, R., Lan, Y., Gong, C., Feng, C., Qi, H., Lin, Y., & Qin, C. (2025) · Medicine · doi:10.1097/md.0000000000041836 · Cited by 39
Chauhan, A., Dubey, S., & Jain, S. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4111 · Cited by 37
Sighencea, M. G., Popescu, R. Ș., & Trifu, S. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212311 · Cited by 38
“Consequently, it is hypothesized that in states of insulin resistance, GSK3 β activity is increased, resulting in increased tau phosphorylation and the subsequent formation of NFTs [104,105].”
Zhang, Y., Yuan, Y., Zhang, J., Zhao, Y., Zhang, Y., & Fu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1004557 · Cited by 38
“Multiple studies have demonstrated that excessive oxidative stress accompanied by impaired antioxidant capacity in T2DM encouraged the generation of ROS that further led to neuronal damage and cognitive dysfunction in T2DM (Valko et al., 2007; Gocmez et al., 2019; Michailidis et al., 2022).”
BackgroundMancinetti, F., Xenos, D., Fano, M. D., Mazzieri, A., Porcellati, F., Boccardi, V., & Mecocci, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102018 · Cited by 37
Gao, X., Sun, H., Wei, Y.-D., Niu, J., Hao, S., Sun, H., Tang, G., Qi, C., & Ge, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155805 · Cited by 35
Tian, H., Wei, J.-W., Zheng, J., Luo, Q.-Y., Hu, X.-R., Du, Q., Cai, Y., & Zhang, S. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02465-1 · Cited by 33
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Złotek, M., Kurowska, A., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Biomedicines · doi:10.3390/biomedicines11113035 · Cited by 32
“AD is now recognized as a type 3 diabetes due to neuroendocrine aspects [84].”
BackgroundPharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
Adem, M. A., Decourt, B., & Sabbagh, M. N. (2024) · Biomedicines · doi:10.3390/biomedicines12010099 · Cited by 34
“This is in line with emerging research that has linked AD with common T2DM phenomena, such as insulin resistance, dysfunctional insulin signaling, neuroinflammation, advanced glycosylation end products (AGEs), and metabolic dysfunction [22], earning it the name “type 3 diabetes” [23].”
BackgroundCausal cardiovascular risk factors for dementia: insights from observational and genetic studies
Kjeldsen, E. W., & Frikke‐Schmidt, R. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae235 · Cited by 39
“108,122 Taken together, the current evidence suggests a causal association be-tween Type 2 diabetes and both AD and VaD.”
Vandersmissen, J., Dewachter, I., Cuypers, K., & Hansen, D. (2025) · Sports Medicine - Open · doi:10.1186/s40798-025-00836-7 · Cited by 33
“We refer to extensive reviews regarding T2DM and AD for further reading [24, 108, 109].”
Potential common pathogenesis of several neurodegenerative diseases
Fan, T., Peng, J., Liang, H., Chen, W., Wang, J., & Xu, R. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01054 · Cited by 31
Sulforaphane: An emerging star in neuroprotection and neurological disease prevention
Wu, N., Luo, Z., Deng, R., Zhang, Z., Zhang, J., Liu, S., Luo, Z., & Qi, Q. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116797 · Cited by 28
Teixeira, L. C. R., Luizon, M. R., & Gomes, K. B. (2025) · Receptors · doi:10.3390/receptors4010002 · Cited by 31
Chi, H., Song, M. J., Zhang, J., Zhou, J., & Liu, D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289782 · Cited by 31
“Given the high prevalence of cognitive dysfunctions in patients with T2DM and its serious consequences [23, 24], our aim is to summarize the literature and comprehensively assess the effect of acute GV on cognitive function in type 2 diabetes.”
BackgroundXenos, D., Mancinetti, F., Mecocci, P., & Boccardi, V. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102955 · Cited by 29
Jiang, X. J., Li, J., Yao, X., Ding, H., Gu, A., & Zhou, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1361651 · Cited by 32
Xu, F.-Q., & Shi, J. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241307404 · Cited by 29
“In AD, one of the primary pathological characteristics is the excessive phosphorylation of tau protein, which leads to the formation of NFTs.”
Colin, I. M., Szczepanski, L. W., Gérard, A.-C., & Elosegi, J. A. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.16 · Cited by 29
“AD and T2DM share common pathophysiological mechanisms, namely IR, which led some to claim that AD is a metabolic disease caused by IR in the brain, thereby supporting the hypothesis that AD should actually be regarded as type 3 diabetes.(34,36,111) Early 2023 was marked by the announcement made by the FDA to recogniz…”
BackgroundDarbandi, Z. K., Amirahmadi, S., Goudarzi, I., Hosseini, M., & Rajabian, A. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01314-w · Cited by 28
“However, neuro-inflammation and oxidative stress have been considered major pathological characteristics of neurodegenerative disorders (Khan et al. 2020; Michailidis et al. 2022).”
InfluentialElbadawy, N. N., Saad, M. A., Elfarrash, S., Ahmed, M. A. E., & Abdelkader, N. F. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177305 · Cited by 29
Xiao, X., Yan, X., Liang, C., & Yang, Y. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1772036 · Cited by 28
Evidence of disturbed insulin signaling in animal models of Alzheimer’s disease
Alves, S. S., Servilha‐Menezes, G., Rossi, L., da Silva-Júnior, R. M. P., & Garcia‐Cairasco, N. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105326 · Cited by 27
Gut-liver axis in diabetes: Mechanisms and therapeutic opportunities
Abdalla, M. M. I. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i29.109090 · Cited by 30
Helal, M. M., AbouShawareb, H., Abbas, O., Haddad, R., Zain, Y. E., Osman, A. S. A., & Hassan, A. K. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01888-1 · Cited by 23
“Furthermore, studies indicate that diabetics treated with glucagon ‐ like peptide ‐ 1 (GLP ‐ 1) receptor agonists have a reduced risk of PD compared to those on other anti-diabetic medications, suggesting possible neuroprotective effects [9, 10].”
Type 3 Diabetes: Linking Insulin Resistance to Cognitive Decline
Chapple, B. E., Bayliss, E., Woodfin, S., Smith, M., Winter, J., & Moore, W. (2025) · Diseases · doi:10.3390/diseases13110359 · Cited by 25
“De-clining estrogen levels, particularly during menopause, can contribute to cognitive decline and insulin resistance due to the role of estrogens in insulin signaling [3,129,181].”
InfluentialKuang, Y., Wu, Z., Xia, R., Li, X., Liu, J., Dai, Y., Wang, D., & Chen, S. (2022) · Brain Sciences · doi:10.3390/brainsci12101399 · Cited by 23
“The increased tau hyperphosphorylation and intra-neuronal β-amyloid deposition in the brain are results of insulin resistance and hyperinsulinemia [2].”
BackgroundYaribeygi, H., Hemmati, M. A., Nasimi, F. S., Pakdel, R., Jamialahmadi, T., & Sahebkar, A. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114830 · Cited by 25
Huang, X., Huang, S., Fu, F., Song, J., Zhang, Y., & Yue, F. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01416-9 · Cited by 25
Sepúlveda, P., Ferreira, A. F. F., Sandoval, C., Bergoc, G. G., Moreno, A. C. R., Nunes, M. T., & Torrão, A. D. S. (2024) · Cells · doi:10.3390/cells13211793 · Cited by 23
“It is denominated as type 3 diabetes by scientists [14].”
BackgroundAlzarea, E. A., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Beshay, O. N., & Batiha, G. E. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08832-6 · Cited by 23
“According to these findings, AD was proposed as type 3 diabetes due to abnormal insulin signaling and glucose metabolism in the brain (Michailidis et al., 2022).”
Hnilicová, P., Kantorová, E., Šutovský, S., Grofik, M., Zeleňák, K., Kurča, E., Žilka, N., Parvanovova, P., & Kolísek, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043325 · Cited by 24
“Even though glutamate cannot cross the blood-brain barrier (BBB), it can be found in all brain cells with the highest abundance in the synaptic vesicles of nerve terminals, from where it can be released into the synaptic cleft [20,67].”
BackgroundInfluentialRarinca, V., Nicoară, M., Ureche, D., & Ciobica, A. S. (2023) · Antioxidants · doi:10.3390/antiox12071418 · Cited by 24
Tundo, G. R., Grasso, G., Persico, M., Tkachuk, O., Bellia, F., Bocedi, A., Marini, S., Parravano, M., Graziani, G., Fattorusso, C., et al. (2023) · Biomolecules · doi:10.3390/biom13101492 · Cited by 26
Özpak, L., & Bağca, B. G. (2024) · IUBMB Life · doi:10.1002/iub.2902 · Cited by 25
Cozza, A., Chinigò, C., Filicetti, E., Greco, G. I., Lappano, R., Marinaro, C., Muglia, L., Soraci, L., Corsonello, A., Lattanzio, F., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102834 · Cited by 20
Insulin Resistance and Impaired Branched-Chain Amino Acid Metabolism in Alzheimer’s Disease
Liu, R., Zhang, L., & You, H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221147 · Cited by 19
Sun, L., Lu, J.-X., Li, X., Zheng, T., & Zhan, X. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i10.1514 · Cited by 24
Tolédano, A., Rodríguez‐Casado, A., Álvarez, M., & Toledano‐Díaz, A. (2024) · Brain Sciences · doi:10.3390/brainsci14111101 · Cited by 21
Neuroprotective Effects of Ecklonia cava in a Chronic Neuroinflammatory Disease Model
Jo, S.-L., Yang, H. J., Jeong, K. J., Lee, H. W., & Hong, E. (2023) · Nutrients · doi:10.3390/nu15082007 · Cited by 19
Analyzing Immune Cell Infiltration and Copper Metabolism in Diabetic Foot Ulcers
Yi, W.-J., Yuan, Y., Bao, Q., Zhao, Z., Ding, H.-S., & Song, J. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s452609 · Cited by 18
“22 DEGs were found to be enriched in the following items according to the KEGG analysis: CGMP-PKG signaling pathway, AMPK signaling pathway, Thyroid hormone signaling pathway, Insulin signaling pathway, Adipocytokine signaling pathway.”
MethodMetformin’s Effects on Cognitive Function from a Biovariance Perspective: A Narrative Review
Chele, D., Sîrbu, C. A., Mitrică, M., Toma, M., Vasiliu, O., Sirbu, A. M., Authier, F., Mischianu, D. L. D., & Munteanu, A. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041783 · Cited by 18
“…by studies demonstrating overlapping pathological features between insulin resistance, a characteristic of T2D, and Alzheimer’s disease, including amyloid-β accumulation, mitochondrial dysfunction, oxidative stress, chronic neuroinflammation, and impaired glucose metabolism in the brain [11,12].”
Zuffa, S., Allaband, C., Charron‐Lamoureux, V., Caraballo‐Rodríguez, A. M., Patan, A., Mohanty, I., Agongo, J., Bostick, J. W., Connerly, T. J., Thron, T., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117499 · Cited by 20
Alkanad, M. A., Hani, U., Annegowda, H. V., Ghazwani, M., Haider, N., Osmani, R. A. M., Pandareesh, M. D., Hamsalakshmi, & Bhat, R. (2024) · BioFactors · doi:10.1002/biof.2034 · Cited by 19
Zhuge, F., Zheng, L., Pan, Y., Ni, L., Fu, Z., Shi, J., & Ni, Y. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114689 · Cited by 21
Liu, W., Hu, Q., Zhang, F., Shi, K., & Wu, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21073 · Cited by 18
“AD has been considered type 3 diabetes [36], and a prior study has identified a causal relationship between diabetes and an increased risk of AD [37].”
BackgroundAli, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Bahaa, M. M., Al-Ibrahim, F., & Batiha, G. E. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70118 · Cited by 19
Versace, S., Pellitteri, G., Sperotto, R., Tartaglia, S., Porto, A. D., Catena, C., Gigli, G. L., Cavarape, A., & Valente, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310615 · Cited by 18
“In recent years, sporadic AD has been increasingly considered as a metabolic disorder, characterized by brain insulin resistance and impaired glucose metabolism, which is the main energetic source for neurons [28,29].”
BackgroundMRI and Clinical Biomarkers Overlap between Glaucoma and Alzheimer’s Disease
Martucci, A., Giuliano, F. D., Minosse, S., Pocobelli, G., Nucci, C., & Garaci, F. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914932 · Cited by 20
“Consequently, it affects the patient’s personality and social life [52,53].”
BackgroundUğraş, Z., Tok, F., Çakır, C., Tuna, K., Tatar, G., Mutlu, D., Sıcak, Y., Arslan, Ş., Öztürk, M., & Koçyiğit‐Kaymakçıoğlu, B. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138978 · Cited by 19
García-Zamora, M., García‐Lluch, G., Moreno, L., Pardo, J., & Cháfer-Pericas, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107295 · Cited by 16
Ilić, I., Jakovljevic, V. L., Mačužić, I. Ž., Ravić‐Nikolić, A., Ilić, M., Šorak, M., & Milicic, V. M. (2024) · Medicina · doi:10.3390/medicina60111783 · Cited by 20
Farag, M. M., Abdelmalak, N. S., Menshawe, S. F. E., Omara, A. S., & Hamad, D. S. (2025) · Journal of Microencapsulation · doi:10.1080/02652048.2025.2500542 · Cited by 18
“…brain insulin resistance, pancreatic and brain degeneration, protein aggregation, elevated inflammatory response, dysregulated protein phosphorylation, elevated glycogen synthase kinase-3 beta (GSK-3 beta) action, oxidative stress, in addition to mitochondrial dysfunction (Michailidis et al. 2022).”
Zou, Y., Wang, Q., & Cheng, X. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00458-9 · Cited by 16
Gandhi, A., & Parhizgar, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1708565 · Cited by 18
Guo, X., Yang, Y., Zhou, R., Tian, G., Shan, C., Liu, J., & Li, R. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02924-w · Cited by 19
“Finally, the fi ndings of this study were based on individuals of European descent, and further validation in other racial/ethnic groups is needed.”
Fluca, A. L., Pani, B., Janjusevic, M., Zwas, D. R., Abraham, Y., Calligaris, M., Beltrami, A. P., Corgosinho, F. C., Marketou, M. E., D’Errico, S., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122911 · Cited by 16
Targeting Metabolic Dysregulation in Alzheimer’s Disease: A Potential Therapeutic Strategy
Barnwal, N., Dubey, S., & Tiwari, P. K. (2025) · Current Drug Metabolism · doi:10.2174/0113892002408089250912080734 · Cited by 190
Matching science to reality: how to deploy a participant-driven digital brain health platform
Anda‐Duran, I. D., Hwang, P. H., Popp, Z., Low, S., Ding, H., Rahman, S., Igwe, A., Kolachalama, V. B., Lin, H., & Au, R. (2023) · Frontiers in Dementia · doi:10.3389/frdem.2023.1135451 · Cited by 14
“Etiological pathways tied to increased risk of ADRD include, but are not limited to, cardiovascular contributors (Stampfer, 2006), diabetes (Kroner, 2009; Michailidis et al., 2022), sleep disorders (Ju et al.”
BackgroundJang, H., Lee, S., An, S., Park, Y., Kim, S.-J., Cheon, B. K., Kim, J. H., Kim, H. J., Na, D. L., Kim, J. P., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207806 · Cited by 18
Non-Genetic Risk Factors of Alzheimer's Disease: An Updated Umbrella Review
He, S.-Y., Su, W.-M., Wen, X.-J., Lu, S.-J., Cao, B., Yan, B., & Chen, Y.-P. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.100 · Cited by 19
“Interestingly, Michailidis et al. (72) posed a hypothesis that AD, a type 3 diabetes, is a metabolic disease caused by insulin resistance because they are interlinked with the above mechanisms.”
BackgroundHayes, C. A., Wilson, D., Leon, M. A. D., Mustapha, M. J., Morales, S., Odden, M. C., & Ashpole, N. M. (2024) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2024.101161 · Cited by 17
Musillo, C., Giona, L., Ristow, M., Zarse, K., Siems, K., Francesco, A. D., Collacchi, B., Raggi, C., Cirulli, F., & Berry, A. (2023) · Nutrients · doi:10.3390/nu15153366 · Cited by 15
Almatary, A. M., Al-Sanea, M. M., Nasr, E. E., Haikal, A., Thompson, G. S., Abood, A., Ibrahim, M. A. A., Elgazar, A. A., & Hamdi, A. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108295 · Cited by 13
Majid, H., Kohli, S., Islam, S. U., & Nidhi (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01597-6 · Cited by 14
Tau Loss of Function, by Deletion or Aggregation, Contributes to Peripheral Insulin Resistance
Al‐Lahham, R., & Méndez, N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230392 · Cited by 13
Zhao, W., Zhang, W. Y., Hu, Y., Zhou, Y., Zhao, J., Li, Y., & Xu, Z. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04162-4 · Cited by 13
Zegarra-Valdivia, J. A., Arana‐Nombera, H. A., Perez‐Fernandez, L. A., Casimiro‐Arana, M. D. R., Gallegos‐Manayay, V. N., Oliva‐Piscoya, M. D. R., Alamo‐Medina, R. E., Abanto‐Saldaña, E. S., Ordinola, M. C. C., Paredes-Manrique, C., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040233 · Cited by 12
Wang, S., Shi, Y., Xin, R., Kang, H., Xiong, H., & Ren, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1614006 · Cited by 17
Nutritional intervention for diabetes mellitus with Alzheimer's disease
Li, Z., Li, S., Xiao, Y., Zhong, T., Yu, X., & Wang, L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1046726 · Cited by 13
Alzheimer's disease, a metabolic disorder: Clinical advances and basic model studies (Review)
Zhou, S., Tu, L., Chen, W., Yan, G., Guo, H., Wang, X., Hu, Q., Liu, H., & Li, F. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12351 · Cited by 14
Wang, Y., Sun, Y., Wang, Y., Jia, S., Qiao, Y., Zhou, Z., Shao, W., Zhang, X., Guo, J., Song, X., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1273807 · Cited by 15
Metadata
- Authors
- Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V.
- Affiliations
- Laboratory of Psychology, School of Psychology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
- Aristotle University of Thessaloniki (GR)
- International Hellenic University (GR)
- Corresponding author
- Papaliagkas, Vasileios
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-28
- Volume
- 23
- Issue
- 5
- Pages
- 2687
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8910482
- OpenAlex
- W4214581316
- Cited by
- 330
- References
- 150
- Citations by year
- 2026: 79 · 2025: 110 · 2024: 71 · 2023: 61 · 2022: 9
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- Alzheimer's disease, type 2 diabetes, type 3 diabetes, insulin resistance, insulin signaling, neuroinflammation, oxidative stress, advanced glycation end products, mitochondrial dysfunction, metabolic syndrome, amyloid-beta, tau protein, amylin, cognitive impairment, brain energy homeostasis
- MeSH terms
- Alzheimer Disease, Brain, Diabetes Mellitus, Type 2, Humans, Insulin, Insulin Resistance, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
